On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
